Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment

Affiliation auteurs!!!! Error affiliation !!!!
TitreAcquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment
Type de publicationJournal Article
Year of Publication2020
AuteursGobert D., Bouillet L., Armengol G., Coppo P., Defendi F., Du-Thanh A., Hardy G., Javaud N., Jeandel P-Y, Launay D., Panayotopoulos V, Pelletier F., Boccon-Gibod I, Fain O.
JournalREVUE DE MEDECINE INTERNE
Volume41
Pagination838-842
Date PublishedDEC
Type of ArticleArticle
ISSN0248-8663
Mots-clésAcquired C1-inhibitor deficiency, Bradykinin, Bradykininin angioedema, C1-inhibitor
Résumé

Acquired angioedema with C1-inhibitor deficiency is a rare and peculiar entity belonging to the spectrumof bradykinin angioedemas. It usually occurs in subjects over 60 years old, and is mostly associated with a B-cell lymphoid hemopathy or a monoclonal gammopathy. The diagnosis relies on at least one angioedema episode, lastingmore than 24 h, and on the decrease of functional C1-inhibitor. LowC1q is observed in 90% of patients, and an anti C1-inhibitor antibody is found in 50% of patients. The treatment of severe attacks relies on icatibant or C1-inhibitor perfusions. Long term prophylaxis in patients with frequent attacks requires treatment of the associated hemopathy if so. In case of idiopathic angioedema, tranexamic acid and danazol may be used, provided that there is-no thrombophilia; as well as rituximab as second-line treatment. Inhibitors of kallikrein still need to be evaluated in this therapeutic indication. (C) 2020 Societe Nationale Francaise de Medecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

DOI10.1016/j.revmed.2020.06.010